ArticleScientific reports2026
Optimization of sporulation of Trametes sanguinea ZHSJ and untargeted metabolomics of spores, mycelium and fruiting body.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Trametes sanguinea belongs to the polyporaceae family and it is a white rot medicinal fungus. In the present study, pure mycelium of Trametes sanguinea ZHSJ (T. sanguinea ZHSJ) was obtained from the fruiting body of wild basidiomycetes by tissue separation method, and its growth conditions were optimized in vitro. The results exhibited the optimal growth of T. sanguinea ZHSJ at pH 5, temperature 30 ℃ with the carbon source maltose 20 g/L and nitrogen source yeast extract 4 g/L. LC-MS based untargeted metabolomic studies revealed there are 6715 metabolites in both positive and negative ion mode detection of spores (SP), mycelium (MY) and fruiting body (MU). However, principal component analysis (PCA) represented PC1 67.10% and PC2 24.60% metabolite variance among SP, MY and MU. Further, metabolite cluster and Variable projection importance (VIP) analysis has represented differential upregulated and down regulated metabolites with p value < 0.05 and VIP ≥ 1 significance. Moreover, KEGG pathway enrichment analysis represented SP vs. MY and SP vs. MY major metabolites 23 and 31 involved in biosynthesis of co-factors and MY vs. MU major metabolites involved in diterpenoid biosynthesis. Hence, current study reveals that the morphological stages of T. sanguinea ZHSJ possess several variations in their metabolites and this is the first study to reveal the optimization of T. sanguinea spores and their metabolites comparison with mycelium and fruiting body through LC-MS based untargeted metabolomics. Further research on the biological activity of these differential metabolites of T. sanguinea spores would way a path in identification of novel medicinally important compounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.